1. Home
  2. MIST vs PSNL Comparison

MIST vs PSNL Comparison

Compare MIST & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIST
  • PSNL
  • Stock Information
  • Founded
  • MIST 2003
  • PSNL 2011
  • Country
  • MIST Canada
  • PSNL United States
  • Employees
  • MIST N/A
  • PSNL N/A
  • Industry
  • MIST Biotechnology: Pharmaceutical Preparations
  • PSNL Medical Specialities
  • Sector
  • MIST Health Care
  • PSNL Health Care
  • Exchange
  • MIST Nasdaq
  • PSNL Nasdaq
  • Market Cap
  • MIST 81.5M
  • PSNL 321.1M
  • IPO Year
  • MIST N/A
  • PSNL 2019
  • Fundamental
  • Price
  • MIST $1.43
  • PSNL $5.19
  • Analyst Decision
  • MIST Strong Buy
  • PSNL Strong Buy
  • Analyst Count
  • MIST 3
  • PSNL 4
  • Target Price
  • MIST $13.00
  • PSNL $6.81
  • AVG Volume (30 Days)
  • MIST 177.8K
  • PSNL 439.4K
  • Earning Date
  • MIST 11-11-2024
  • PSNL 11-06-2024
  • Dividend Yield
  • MIST N/A
  • PSNL N/A
  • EPS Growth
  • MIST N/A
  • PSNL N/A
  • EPS
  • MIST N/A
  • PSNL N/A
  • Revenue
  • MIST N/A
  • PSNL $80,027,000.00
  • Revenue This Year
  • MIST N/A
  • PSNL $10.85
  • Revenue Next Year
  • MIST N/A
  • PSNL $8.77
  • P/E Ratio
  • MIST N/A
  • PSNL N/A
  • Revenue Growth
  • MIST N/A
  • PSNL 19.20
  • 52 Week Low
  • MIST $1.12
  • PSNL $0.89
  • 52 Week High
  • MIST $3.52
  • PSNL $7.20
  • Technical
  • Relative Strength Index (RSI)
  • MIST 42.50
  • PSNL 56.29
  • Support Level
  • MIST $1.41
  • PSNL $4.54
  • Resistance Level
  • MIST $1.53
  • PSNL $5.35
  • Average True Range (ATR)
  • MIST 0.07
  • PSNL 0.30
  • MACD
  • MIST -0.01
  • PSNL 0.05
  • Stochastic Oscillator
  • MIST 26.96
  • PSNL 84.71

About MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

About PSNL Personalis Inc.

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

Share on Social Networks: